Ngm Biopharmaceuticals Stock Price, News & Analysis

NGM Biopharmaceuticals, Inc. (NGM) is a biotechnology company that has traded on the Nasdaq under the symbol NGM and operates in the pharmaceutical preparation manufacturing industry. According to company communications, NGM Bio is focused on discovering and developing novel, life‑changing medicines for people whose health and lives have been disrupted by disease. It emphasizes a biology‑centric drug discovery approach that integrates interrogation of complex disease‑associated biology with protein engineering expertise to generate proprietary product candidates and advance them into proof‑of‑concept studies.

NGM Bio reports that all therapeutic candidates in its pipeline have been generated by its in‑house discovery engine. The company describes this engine as being led by biology and motivated by unmet patient need, with the aspiration to operate one of the most productive research and development engines in the biopharmaceutical industry. Within the broader manufacturing sector, NGM Bio’s activities fall under pharmaceutical preparation manufacturing, with a focus on biologic drug candidates and antibody‑based therapeutics.

Therapeutic Focus Areas and Pipeline Themes

Public disclosures highlight several key areas of focus for NGM Bio’s research and development activities. In solid tumor oncology, the company is evaluating NGM707, described as a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA (pembrolizumab) for patients with advanced or metastatic solid tumors, including microsatellite stable colorectal cancer. NGM Bio has also reported work on NGM831, an ILT3 antagonist antibody product candidate, and NGM438, a LAIR1 antagonist antibody product candidate, in combination with pembrolizumab in patients with advanced solid tumors.

Beyond oncology, NGM Bio has disclosed development activities in liver and metabolic diseases. The company has presented positive Phase 2b results from the ALPINE 4 trial of aldafermin, an engineered FGF19 analog product candidate, in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH). It has also reported plans to further develop aldafermin for the treatment of primary sclerosing cholangitis (PSC), a rare liver disease characterized by bile duct damage and bile acid dysregulation, noting that there are no FDA‑approved therapies for PSC.

NGM Bio has additionally outlined a potential development path for NGM120, described as a GDF15/GFRAL antagonist antibody product candidate. The company has discussed the possible use of NGM120 in hyperemesis gravidarum, a rare and serious condition during pregnancy associated with intractable nausea and vomiting, and has cited research linking elevated GDF15 levels and genetic variants to this condition. NGM Bio characterizes itself as a long‑time explorer of GDF15 biology, including identifying its cognate receptor, GFRAL, and has indicated interest in pursuing a proof‑of‑concept study in this indication.

Biology‑Centric Discovery and Protein Engineering

Across its programs, NGM Bio emphasizes a discovery approach that begins with detailed interrogation of disease‑associated biology. Company descriptions state that this approach is intended to unlock proprietary insights that can be translated into product candidates with optimized pharmacologic profiles. The integration of biology and protein engineering is presented as central to the company’s ability to generate antibody and protein‑based therapeutics targeting specific pathways, such as ILT2, ILT3, ILT4, LAIR1, FGF19 and GDF15/GFRAL.

NGM Bio’s communications also reference a history of generating clinical data across multiple indications, including solid tumors, NASH‑related liver disease, PSC and bile acid‑related conditions. In addition to oncology and rare liver diseases, the company has reported data from a Phase 2 investigator‑sponsored trial of aldafermin in patients with diarrhea‑predominant irritable bowel syndrome with bile acid malabsorption, where it observed reductions in markers of bile acid synthesis and fecal bile acids compared with placebo.

Corporate Structure and Transaction History

NGM Biopharmaceuticals, Inc. has been listed on the Nasdaq under the ticker NGM. In its public announcements, the company has described itself as a biotechnology company focused on discovering and developing transformative therapeutics, with all product candidates generated internally. In 2024, NGM Bio announced that it had entered into an Agreement and Plan of Merger with Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc., affiliates of The Column Group, LP. Subsequent communications reported that Atlas Neon Parent, Inc., through its wholly‑owned subsidiary Atlas Neon Merger Sub, Inc., completed a cash tender offer to acquire all outstanding shares of NGM Bio not held by affiliates of The Column Group and certain other stockholders.

Following the closing of the tender offer, NGM Bio reported that Merger Sub merged with and into NGM Bio, with NGM Bio surviving the merger as a privately held, wholly‑owned subsidiary of Atlas Neon Parent, Inc. The company stated that, prior to the opening of trading on Nasdaq on April 5, 2024, all shares of NGM Bio common stock ceased trading on Nasdaq and that NGM Bio intended to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended. These disclosures indicate that NGM Bio transitioned from a publicly traded company to a privately held entity as a result of the transaction.

Industry Context and Areas of Unmet Need

Within the pharmaceutical preparation manufacturing and biotechnology landscape, NGM Bio’s disclosed programs focus on areas characterized in its communications as having significant unmet medical need. These include advanced solid tumors that may be less responsive to existing immunotherapies, rare liver diseases such as PSC without approved treatments, and hyperemesis gravidarum, which the company notes currently lacks FDA‑approved therapies. NGM Bio’s emphasis on biology‑driven discovery and protein engineering is presented as a way to address complex mechanisms underlying these conditions.

While detailed financial metrics and specific timelines are subject to change and are not the focus of this overview, NGM Bio’s public statements highlight ongoing clinical trials, regulatory interactions and exploratory development plans across its oncology, liver disease and pregnancy‑related programs. Investors and observers considering the historical NGM stock and the company’s evolution can use this context to understand the scientific themes and therapeutic areas that have shaped NGM Bio’s strategy.

Frequently Asked Questions about NGM Biopharmaceuticals, Inc. (NGM)

• What does NGM Biopharmaceuticals, Inc. focus on?
  NGM Bio states that it focuses on discovering and developing novel, life‑changing medicines for people whose health and lives have been disrupted by disease. Its approach is described as biology‑centric, integrating interrogation of complex disease‑associated biology with protein engineering to generate proprietary product candidates.
• What therapeutic areas has NGM Bio highlighted?
  Company communications describe work in solid tumor oncology, including product candidates such as NGM707, NGM831 and NGM438 in combination with pembrolizumab, as well as liver and metabolic diseases involving aldafermin. NGM Bio has also discussed potential development of NGM120 for hyperemesis gravidarum.
• What is aldafermin and where is it being studied?
  Aldafermin is described by NGM Bio as an engineered FGF19 analog product candidate. It has been evaluated in the Phase 2b ALPINE 4 trial in patients with compensated cirrhosis due to NASH, and the company has reported plans to further develop aldafermin for primary sclerosing cholangitis, a rare liver disease with no FDA‑approved therapies.
• What is NGM707?
  NGM707 is characterized as a dual ILT2/ILT4 antagonist antibody product candidate. NGM Bio has reported encouraging findings from an ongoing Phase 1/2 trial evaluating NGM707 in combination with KEYTRUDA (pembrolizumab) in patients with advanced or metastatic solid tumors, including microsatellite stable colorectal cancer.
• How does NGM Bio describe its discovery engine?
  NGM Bio states that all therapeutic candidates in its pipeline have been generated by its in‑house discovery engine. This engine is described as always led by biology and motivated by unmet patient need, with the goal of efficiently advancing product candidates into proof‑of‑concept studies.
• What is NGM120 and what condition is it being considered for?
  NGM120 is described as a GDF15/GFRAL antagonist antibody product candidate. NGM Bio has discussed the potential development of NGM120 for hyperemesis gravidarum, a rare and serious pregnancy‑related condition, referencing research that links higher GDF15 levels and genetic variants to this condition.
• What corporate transaction affected NGM Bio’s stock listing?
  NGM Bio announced an Agreement and Plan of Merger with Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc., affiliates of The Column Group, LP. Following a cash tender offer and subsequent merger, NGM Bio reported that it became a privately held, wholly‑owned subsidiary of Atlas Neon Parent, Inc., and that its common stock ceased trading on Nasdaq with plans for delisting and deregistration.
• Does NGM Bio still trade under the ticker NGM?
  Public statements from the company indicate that, prior to the opening of trading on April 5, 2024, all shares of NGM Bio common stock ceased trading on Nasdaq in connection with its acquisition by Atlas Neon Parent, Inc., and that NGM Bio intended to delist and deregister its shares. These disclosures suggest that NGM Bio no longer trades as a publicly listed stock under the NGM symbol.